UC Patients Taking Ozanimod in Phase 2 Trial Show Histologic Improvement, Celegene Reports

UC Patients Taking Ozanimod in Phase 2 Trial Show Histologic Improvement, Celegene Reports
Celgene International Sàrl, a subsidiary of Celgene Corporation, has announced the release of additional data on exploratory endpoints from its Phase 2 clinical trial assessing ozanimod in people with moderate to severe ulcerative colitis (UC). The data, showing improvements in histologic measures and remission, was presented at the recent 11th Congress of the European Crohn’s and Colitis Organization (ECCO) in Amsterdam. Ozanimod is a small molecule sphingosine 1-phosphate (S1P) 1 and 5 receptor modulator in development for immune-inflammatory indications. Treatment with S1P receptor modulators is designed to work by interfering with S1P signaling and blocking the response of lymphocytes to exit signals from the lymph nodes. This process results in a reduction of circulating lymphocytes and anti-inflammation activity, by inhibiting the migration of pathologic lymphocytes to inflammation sites. Results presented at ECCO indicated that ozanimod 1mg treatment led to histologic improvement and remission in patients over 32 weeks. “It’s exciting to observe histologic improvements in patients with ulcerative colitis who were treated with ozanimod. Clinical research suggests that histologic improvements can be linked with improved clinical outcomes in ulcerative colitis,” Dr. William Sandborn, a professor of medicine at University of California San Diego, said in a press release. “While often more difficult to measure, endpoints such as histologic improv
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *